Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $29.75

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has been assigned an average rating of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $29.75.

Several equities analysts have commented on JSPR shares. Cantor Fitzgerald cut Jasper Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, July 7th. JMP Securities cut their price target on Jasper Therapeutics from $70.00 to $12.00 and set a "market outperform" rating for the company in a report on Tuesday, July 8th. Royal Bank Of Canada cut Jasper Therapeutics from an "outperform" rating to a "sector perform" rating and set a $5.00 price target for the company. in a report on Tuesday, July 8th. UBS Group cut their price target on Jasper Therapeutics from $38.00 to $33.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Finally, BMO Capital Markets reaffirmed a "market perform" rating on shares of Jasper Therapeutics in a report on Tuesday, July 8th.

Hedge Funds Weigh In On Jasper Therapeutics

Large investors have recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new position in shares of Jasper Therapeutics during the first quarter worth approximately $46,000. Corton Capital Inc. acquired a new position in shares of Jasper Therapeutics during the first quarter worth approximately $113,000. Wells Fargo & Company MN lifted its position in shares of Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after purchasing an additional 3,828 shares in the last quarter. EntryPoint Capital LLC acquired a new position in shares of Jasper Therapeutics during the fourth quarter worth approximately $223,000. Finally, Tema Etfs LLC acquired a new position in shares of Jasper Therapeutics during the fourth quarter worth approximately $266,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Trading Up 3.8%

JSPR traded up $0.12 during midday trading on Friday, reaching $3.27. The company's stock had a trading volume of 276,471 shares, compared to its average volume of 403,466. The stock has a market cap of $49.12 million, a P/E ratio of -0.62 and a beta of 2.69. The company has a fifty day simple moving average of $4.95 and a 200 day simple moving average of $5.34. Jasper Therapeutics has a twelve month low of $2.27 and a twelve month high of $26.05.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.24). Sell-side analysts expect that Jasper Therapeutics will post -4.47 earnings per share for the current year.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.